Kyntra BioLTS:0IL8 -1.94%50 Days Payable is 98.22 as of Mar. 2026, which is 86% below its 10-year median of 721.52. GuruFocus rates LTS:0IL8 with a GF Score™ of 50/100 and a GF Value™ of $5.70 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 700 Biotechnology companies, Kyntra Bio ranks better than 79.86% on this metric.
Kyntra Bio's average Accounts Payable for the
three
months ended in Mar. 2026 was $4.42 Mil. Kyntra Bio's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $4.11 Mil.
Hence, Kyntra Bio's Days Payable for the
three
months ended in Mar. 2026 was 98.22.
The historical rank and industry rank for Kyntra Bio's Days Payable or its related term are showing as below:
LTS:0IL8'
s Days Payable Range Over the Past 10 Years
Min: 244.44 Med: 721.52 Max: 2891.44
Current: 524.47
During the past 13 years, Kyntra Bio's highest Days Payable was 2891.44. The lowest was 244.44. And the median was 721.52.
LTS:0IL8's Days Payable is ranked better than 79.86% of 700
companies
in the Biotechnology industry
Industry Median: 112.83
vs LTS:0IL8: 524.47
Kyntra Bio's Days Payable
declined
from Mar. 2025 (2,235.26) to Mar. 2026 (98.22).
It may suggest that Kyntra Bioaccelerated paying its suppliers.
Kyntra Bio Days Payable Related Terms
Kyntra Bio Days Payable Historical Data
* Premium members only.
The historical data trend for Kyntra Bio's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0IL8 vs TVGN, PSTV, GRDX: Days Payable Comparison
For the Biotechnology subindustry, Kyntra Bio's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kyntra Bio Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kyntra Bio's Days Payable distribution charts can be found below:
* The bar in red indicates where Kyntra Bio's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Kyntra Bio's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kyntra Bio (LTS:0IL8) has a Days Payable of 98.22 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Kyntra Bio and its competitors. This is 86% below median its historical median of 721.52. Over the past decade, Kyntra Bio's Days Payable has ranged from 244.44 to 2,891.44. According to the industry distribution chart, Kyntra Bio ranks #141 out of 700 companies in the Biotechnology industry, placing it in the top 20.1%.
Is Kyntra Bio's Days Payable too high?
Kyntra Bio's current Days Payable of 98.22 is 86% below median its 10-year median of 721.52. Over the past 10 years, this metric has ranged from a low of 244.44 to a high of 2,891.44. The Biotechnology industry median Days Payable is 112.83. Kyntra Bio's value of 98.22 is 12.9% below this industry median. Based on the distribution chart, Kyntra Bio ranks #141 out of 700 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Kyntra Bio has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kyntra Bio's Days Payable compare to TVGN and PSTV?
According to the Biotechnology industry distribution chart, Kyntra Bio ranks #141 out of 700 companies for Days Payable. This places Kyntra Bio in the top 20% of its industry — outperforming the majority of peers. The industry median Days Payable is 112.83. Kyntra Bio's value of 98.22 is 12.9% below this benchmark. Historically, Kyntra Bio's own Days Payable has ranged from 244.44 to 2,891.44 over the past decade. While the company's 10-year median is 721.52 vs. the industry median of 112.83, Kyntra Bio has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.83, based on 700 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kyntra Bio's current Days Payable of 98.22 is 12.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Kyntra Bio and its competitors. For the Biotechnology industry, the median Days Payable is 112.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kyntra Bio's current Days Payable is 98.22, which is 86% below median its own 10-year median of 721.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyntra Bio stock overvalued right now?
Based on GuruFocus' analysis, Kyntra Bio (LTS:0IL8) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.70, compared to a current price of $7.45 — trading 30.8% above its estimated fair value. The current Days Payable is 98.22, which is 86% below median its 10-year median of 721.52 and 12.9% below the Biotechnology industry median of 112.83. Kyntra Bio's overall GF Score™ is 50/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Kyntra Bio (LTS:0IL8), the current Days Payable is 98.22 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kyntra Bio (LTS:0IL8) Overvalued in 2026?
Based on GuruFocus' analysis, Kyntra Bio stock appears to be overvalued.
The current stock price of $7.45 is trading 30.8% above its estimated GF Value™ of $5.70.
GuruFocus considers Kyntra Bio to be Significantly Overvalued.
Key valuation signals for LTS:0IL8:
Days Payable: 98.22 (86% below median its 10-year median of 721.52)
GF Value™: $5.70 vs. price of $7.45 (30.8% above fair value)
Industry Position: 12.9% below the Biotechnology median (#141 of 700)
No single metric tells the full story. See the LTS:0IL8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
50GF Score
Get the complete analysis for LTS:0IL8
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0IL8 has been successfully added to your 
